Sorbitol
Sorbitol (sorbitol) is a small molecule pharmaceutical. Sorbitol was first approved as Sorbitol-mannitol in plastic container on 1982-01-01. It is used to treat constipation and poisoning in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Sorbitol (discontinued: Sorbitol)
CombinationsSorbitol-mannitol (discontinued: Sorbitol-mannitol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mannitol
+
Sorbitol
Sorbitol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SORBITOL 3.3% IN PLASTIC CONTAINER | B. Braun Medical | N-016741 RX | 1982-01-01 | 1 products |
| SORBITOL 3% IN PLASTIC CONTAINER | Baxter | N-017863 RX | 1982-01-01 | 1 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| anubis barcelona | OTC monograph final | 2023-09-01 |
| gericare sorbitol solution | C200263 | 2024-12-20 |
| insta-char sorbitol | C200263 | 2025-01-13 |
| sorbitol | New Drug Application | 2019-12-31 |
| sorbitol-mannitol | New Drug Application | 2021-04-07 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A06: Drugs for constipation
— A06A: Drugs for constipation
— A06AD: Osmotically acting laxatives
— A06AD18: Sorbitol
— A06AG: Enema for constipation
— A06AG07: Sorbitol
B: Blood and blood forming organ drugs
— B05: Blood substitutes and perfusion solutions
— B05C: Irrigating solutions, blood substitutes and perfusion
— B05CX: Other irrigating solutions in atc
— B05CX02: Sorbitol
V: Various drug classes in atc
— V04: Diagnostic agents
— V04C: Other diagnostic agents in atc
— V04CC: Diagnostic agents for bile duct patency testing
— V04CC01: Sorbitol
HCPCS
No data
Clinical
Clinical Trials
203 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leishmaniasis | D007896 | EFO_0005044 | B55 | 1 | 11 | 12 | 4 | 1 | 25 |
| Cutaneous leishmaniasis | D016773 | — | B55.1 | 1 | 10 | 11 | 2 | 1 | 22 |
| Healthy volunteers/patients | — | — | — | 5 | — | — | 2 | 1 | 8 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 1 | 2 | 3 | 1 | 8 |
| Syndrome | D013577 | — | — | — | — | 1 | 1 | 5 | 7 |
| Intestinal obstruction | D007415 | — | K56.60 | — | 1 | 2 | 2 | 2 | 6 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | 4 | — | 5 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | 2 | 3 | 5 |
| Dental caries | D003731 | EFO_0003819 | K02 | — | 2 | 1 | 1 | 1 | 4 |
| Coronary disease | D003327 | — | — | — | — | 1 | 2 | — | 3 |
Show 39 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | 2 | 5 | 1 | — | — | 7 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 4 | 1 | — | — | 6 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 2 | 2 | — | 3 | 5 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 2 | 2 | — | 2 | 4 |
| Charcot-marie-tooth disease | D002607 | EFO_0004148 | G60.0 | — | — | 3 | — | — | 3 |
| Iron-deficiency anemia | D018798 | — | D50 | — | — | 3 | — | — | 3 |
| Iron deficiencies | D000090463 | — | E61.1 | — | — | 3 | — | — | 3 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | 1 | — | — | 2 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | 1 | — | — | 2 |
| Cardio-renal syndrome | D059347 | — | — | — | — | 1 | — | 1 | 2 |
Show 44 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | 2 | — | — | 1 | 4 |
| Inflammation | D007249 | MP_0001845 | — | 1 | 1 | — | — | 3 | 4 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | 1 | — | — | 1 | 3 |
| Gingivitis | D005891 | — | K05.10 | 1 | 2 | — | — | 1 | 3 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 2 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 2 | 2 | — | — | — | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 2 | — | — | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | 1 | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | 1 | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | — | — | — | 2 |
Show 39 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | 2 | — | — | — | — | 2 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Middle east respiratory syndrome coronavirus | D065207 | — | — | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Duchenne muscular dystrophy | D020388 | EFO_0000429 | — | 1 | — | — | — | — | 1 |
| Muscular dystrophies | D009136 | EFO_0000757 | G71.0 | 1 | — | — | — | — | 1 |
| Feeding and eating disorders | D001068 | — | F50 | 1 | — | — | — | — | 1 |
| West nile fever | D014901 | EFO_0007545 | A92.3 | 1 | — | — | — | — | 1 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | — | — | — | — | 1 |
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 5 | 5 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | — | — | 4 | 4 |
| Food hypersensitivity | D005512 | EFO_1001890 | — | — | — | — | — | 3 | 3 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | — | — | — | — | 2 | 2 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 2 | 2 |
| Hypoglycemia | D007003 | — | E16.2 | — | — | — | — | 1 | 1 |
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | — | — | — | — | 1 | 1 |
| Colorectal neoplasms | D015179 | — | — | — | — | — | — | 1 | 1 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | — | — | — | 1 | 1 |
| Xerostomia | D014987 | — | K11.7 | — | — | — | — | 1 | 1 |
Show 37 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sorbitol |
| INN | — |
| Description | D-glucitol is the D-enantiomer of glucitol (also known as D-sorbitol). It has a role as a sweetening agent, a laxative, a metabolite, a cathartic, a human metabolite, a food humectant, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite and a mouse metabolite. It is an enantiomer of a L-glucitol. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO |
Identifiers
| PDB | — |
| CAS-ID | 50-70-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1682 |
| ChEBI ID | 17924 |
| PubChem CID | 5780 |
| DrugBank | DB01638 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Sorbitol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 58,776 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
405 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use